阿托伐他汀联合阿仑膦酸钠治疗骨质疏松症的效果

摘要
图/表
参考文献(19)
相关文章 (15)

全文: PDF (0 KB) HTML (40 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨阿托伐他汀联合阿仑膦酸钠治疗骨质疏松症的效果。方法选取2017年2月～2018年6月我院收治的80 例骨质疏松患者作为研究对象，按照随机数字表法将其分为对照组（40 例）和研究组（40 例）。对照组患者接受单一的阿仑膦酸钠片治疗，研究组患者接受阿托伐他汀联合阿仑膦酸钠治疗。比较两组患者的临床疗效及治疗前后不同部位骨密度、不同生化指标，如碱性磷酸酶（ALP）、钙（Ca）、骨钙素（BGP）及人25 羟基维生素D、[25（OH）D]，并记录两组患者的不良反应发生情况。结果研究组患者的治疗总有效率高于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者腰椎、股骨、股骨颈及股骨粗隆的骨密度比较，差异无统计学意义（P＞0.05）；治疗后，两组患者腰椎、股骨、股骨颈及股骨粗隆的骨密度均高于治疗前，差异有统计学意义（P＜0.05）；研究组患者治疗后腰椎、股骨、股骨颈及股骨粗隆的骨密度均高于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者的ALP、Ca、BGP 及25（OH）D 水平比较，差异无统计学意义（P＞0.05）；治疗后，两组患者的ALP、Ca、BGP 及25（OH）D水平均高于治疗前，差异有统计学意义（P＜0.05）；研究组患者治疗后的ALP、Ca、BGP 及25（OH）D 水平均高于对照组，差异有统计学意义（P＜0.05）。研究组患者的不良反应总发生率低于对照组，差异有统计学意义（P＜0.05）。结论使用阿托伐他汀联合阿仑膦酸钠治疗骨质疏松症具有比较理想的临床效果，能够有效缓解患者的临床症状，同时安全性较高，可以减少不良反应的发生，临床上值得进一步推广应用。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：阿托伐他汀, 阿仑膦酸钠, 骨质疏松, 骨密度

Abstract：Objective To investigate the effect of Atorvastatin combined with Alendronate in the treatment of osteoporosis. Methods Eighty patients with osteoporosis admitted to our hospital from February 2017 to June 2018 were selected as the research objects, and they were divided into the control group (40 cases) and the study group (40 cases)according to the random number table method. Patients in control group were treated with Alendronate Tablets alone,while patients in the study group received Atorvastatin combined with Alendronate. The clinical efficacy, bone mineral density at different parts, different biochemistry indexes (alkaline phosphatase [ALP], calcium [Ca], bone gla protein[BGP], and human 25-hydroxyvitamin D [25(OH)D]) before and after treatment were compared between the two groups.The occurrence of adverse reactions between the two groups was recorded. Results The total effective rate of treatment in the study group was higher than that in the control group, and the difference was statistically significant (P＜0.05).Before treatment, there were no significant differences in the bone densities of the lumbar spine, femur, femoral neck,and femoral trochanter between the two groups (P＞0.05). After treatment, the bone densities of the lumbar spine, femur,femoral neck, and femoral trochanter in the two groups were higher than those before treatment, and the differences were statistically significant (P ＜0.05). The bone densities of the lumbar spine, femur, femoral neck, and femoral trochanter in the study group after treatment were higher than those in the control group, and the differences were statistically significant (P＜0.05). Before treatment, there were no significant differences in the levels of ALP, Ca, BGP and 25(OH)D between the two groups (P＞0.05). After treatment, the levels of ALP, Ca, BGP and 25(OH)D in the two groups were higher than those before treatment, and the differences were statistically significant (P＜0.05). The levels of ALP,Ca, BGP and 25(OH)D in the study group after treatment were higher than those in the control group, and the differences were statistically significant (P＜0.05). The total occurrence rate of adverse reactions of the study group was lower than that of the control group, and the difference was statistically significant (P＜0.05). Conclusion The use of Atorvastatin combined with Alendronate in the treatment of osteoporosis has an ideal clinical effect, which can effectively alleviate the clinical symptoms of patients, with high safety at the same time, and greatly reduce the occurrence of adverse reactions, which is worthy of further promotion and application in the clinic.

Key words： Atorvastatin Alendronate Osteoporosis Bone mineral density

引用本文:

冉静;高燕;胡蕖. 阿托伐他汀联合阿仑膦酸钠治疗骨质疏松症的效果[J]. 中国当代医药, 2020, 27(6): 8-11.
RAN Jing GAO Yan HU Qu. Effect of Atorvastatin combined with Alendronate in the treatment of osteoporosis. 中国当代医药, 2020, 27(6): 8-11.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2020/V27/I6/8

[1]	雷雷，郑瑞芝，王月霞，等.阿托伐他汀联合阿仑膦酸钠治疗老年性骨质疏松的临床疗效及安全性[J].中国骨质疏松杂志，2016，22（8）：1031-1034.
[2]	王玮琪，茹选良，刘春，等.阿托伐他汀联合阿仑膦酸钠治疗老年性骨质疏松的临床疗效及安全性评价[J].中国临床药理学杂志，2016，12（4）：312-314.
[3]	中华医学会骨质疏松和骨矿盐疾病分会.原发性骨质疏松症诊治指南（2011年）[J].中华骨质疏松和骨矿盐疾病杂志，2011，4（1）：2-17.
[4]	Tan W，Sun J，Zhou L，et al.Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis[J].J Clin Pharm Ther，2016，41（5）：519-523.
[5]	唐永亮，张静怡，杨寅.阿仑膦酸钠联合钙尔奇D 对骨质疏松症患者疼痛和骨密度的影响[J].临床药物治疗杂志，2017，15（6）：39-43.
[6]	王芳，任汉强，沈晓波.胰岛素联合阿仑膦酸钠对老年糖尿病骨质疏松症患者骨密度及血清BAP、TRAP-5b、BGP水平影响[J].海南医学院学报，2016，22（13）：1387-1389，1393.
[7]	Naylor KE，Bradburn M，Paggiosi MA.Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density[J].Osteoporos Int，2018，29（6）：1407-1417.
[8]	郦文琴，石春晖.阿仑膦酸钠联合碳酸钙D3 片对糖尿病性骨质疏松症患者骨密度、骨代谢指标的影响[J].广西医科大学学报，2016，33（5）：831-833.
[9]	Yoo JI，Ha YC，Won YY，et al.Fracture preventing effects of MaxmarvilRTablets（Alendronate 5 mg+Calcitriol 0.5 μg）in patients with osteoporosis[J].J Bone Metab，2017，24（2）：91-96.
[10]	刘克春，刘世珑，刘国胜，等.全髋关节置换术联合阿仑膦酸钠片对股骨颈骨折的疗效及对骨密度水平的影响[J].中国药房，2018，29（9）：1278-1281.
[11]	Reginster JY.Treatment of postmenopausal osteoporosis[J].BMJ，2016，10（7）：41-47.
[12]	付远锋，李家伟，陈阳斌，等.阿仑膦酸钠片联合骨碎补煎剂对老年骨质疏松患者血清MMP-9 和TNF-α 水平的影响[J].现代生物医学进展，2016，16（29）：5756-5759.
[13]	丛宝华，赵方，宋飞，等.胰岛素联合阿仑膦酸钠对2 型糖尿病骨质疏松症患者骨代谢的影响[J].现代生物医学进展，2017，17（3）：516-519.
[14]	Yano T，Mei Y，Inoue D.Effect of sequential treatment with Bisphosphonates after Teriparatide in ovariectomized rats：a direct comparison between Risedronate and Alendronate[J].Calcif Tissue Int，2017，101（1）：102-110.
[15]	尹立，钟凤林，刘绍江，等.阿托伐他汀联合阿司匹林对绝经期冠心病妇女骨密度及骨生化和代谢的影响[J].中国骨质疏松杂志，2017，23（9）：1149-1152.
[16]	高卫辉，吴芬芬，段小青，等.杜仲-牛膝药对干预去卵巢骨质疏松大鼠雌二醇和骨密度的影响实验研究[J].中南药学，2016，14（8）：820-823.
[17]	黎宗保.激素替代疗法联合阿仑膦酸钠治疗对绝经后骨质疏松症患者子宫内膜及骨代谢的影响[J].山东医药，2016，56（25）：90-92.
[18]	王康振，杨健松，张会良，等.骨力胶囊联合阿仑膦酸钠维D3片治疗老年骨质疏松的疗效及对骨代谢标记物及骨强度的影响[J].中国老年学杂志，2018，38（4）：864-866.
[19]	陈国仙，王国荣，李国山，等.低强度复合振动联合阿仑膦酸钠对绝经后骨质疏松患者骨密度的影响研究[J].中国康复医学杂志，2017，32（2）：182-186.